Posted by Michael Wonder on 26 Feb 2018
EU clears rare musculoskeletal disorder drug
26 February 2018 - Doctors can now treat children living in the EU with the rare, chronic progressive musculoskeletal disorder X–Linked Hypophosphataemia with Kyowa Kirin/Ultragenyx’ Crysvita following its conditional approval in the region.
In children, the condition causes skeletal disease, leading to lower-extremity deformity and diminished height. Conventional treatment consists of multiple daily doses of phosphate and active vitamin D to counteract the excess effects of FGF23, but does not correct the underlying disease.
Crysvita (burosumab), an anti-FGF23 fully human monoclonal antibody, is the first treatment to target the underlying pathophysiology of XLH.
